SEHK:2327

Stock Analysis Report

Meilleure Health International Industry Group

Executive Summary

Meilleure Health International Industry Group Limited, an investment holding company, trades in health care products, and construction and chemical materials in Hong Kong and Mainland China.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.

Risks

  • Meilleure Health International Industry Group has significant price volatility in the past 3 months.
  • Meilleure Health International Industry Group is covered by less than 3 analysts.

Share Price & News

How has Meilleure Health International Industry Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9.6%

SEHK:2327

7.5%

HK Trade Distributors

2.5%

HK Market


1 Year Return

50.0%

SEHK:2327

16.1%

HK Trade Distributors

-3.9%

HK Market

2327 outperformed the Trade Distributors industry which returned 16.1% over the past year.

2327 outperformed the Market in Hong Kong which returned -3.9% over the past year.


Share holder returns

2327IndustryMarket
7 Day9.6%7.5%2.5%
30 Day7.5%22.1%7.6%
90 Day-9.5%23.3%0.8%
1 Year50.0%50.0%19.6%16.1%-0.4%-3.9%
3 Year39.7%37.3%4.8%-4.7%19.6%7.6%
5 Year75.7%72.7%-29.4%-42.8%17.7%-1.7%

Price Volatility Vs. Market

How volatile is Meilleure Health International Industry Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Meilleure Health International Industry Group undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Meilleure Health International Industry Group's share price is below the future cash flow value, and at a moderate discount (> 20%).

Meilleure Health International Industry Group's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Meilleure Health International Industry Group is overvalued based on earnings compared to the HK Trade Distributors industry average.

Meilleure Health International Industry Group is overvalued based on earnings compared to the Hong Kong market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Meilleure Health International Industry Group, we can't assess if its growth is good value.


Price Based on Value of Assets

Meilleure Health International Industry Group is overvalued based on assets compared to the HK Trade Distributors industry average.


Next Steps

Future Growth

How is Meilleure Health International Industry Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

2.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Meilleure Health International Industry Group's revenue is expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).

Meilleure Health International Industry Group's earnings are expected to grow by 2.1% yearly, however this is not considered high growth (20% yearly).

Meilleure Health International Industry Group's revenue growth is positive but not above the Hong Kong market average.

Meilleure Health International Industry Group's earnings growth is positive but not above the Hong Kong market average.

Meilleure Health International Industry Group's earnings growth is expected to exceed the low risk savings rate of 2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Meilleure Health International Industry Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Meilleure Health International Industry Group performed over the past 5 years?

42.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Meilleure Health International Industry Group has delivered over 20% year on year earnings growth in the past 5 years.

Meilleure Health International Industry Group's 1-year earnings growth is less than its 5-year average (1.9% vs 42.1%)

Meilleure Health International Industry Group's earnings growth has exceeded the HK Trade Distributors industry average in the past year (1.9% vs 0.6%).


Return on Equity

Meilleure Health International Industry Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Meilleure Health International Industry Group used its assets more efficiently than the HK Trade Distributors industry average last year based on Return on Assets.


Return on Capital Employed

Meilleure Health International Industry Group has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Meilleure Health International Industry Group's financial position?


Financial Position Analysis

Meilleure Health International Industry Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Meilleure Health International Industry Group's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Meilleure Health International Industry Group's level of debt (31.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (101% vs 31.3% today).

Debt is well covered by operating cash flow (32.7%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 4.2x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.7x debt.


Next Steps

Dividend

What is Meilleure Health International Industry Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Meilleure Health International Industry Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Meilleure Health International Industry Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Meilleure Health International Industry Group has not reported any payouts.

Unable to verify if Meilleure Health International Industry Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Meilleure Health International Industry Group has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Meilleure Health International Industry Group's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average management tenure


CEO

Wen Chuan Zhou (36yo)

6yrs

Tenure

HK$540,000

Compensation

Ms. Wen Chuan Zhou has been the Chief Executive Officer and Executive Director of U-Home Group Holdings Limited since September 23, 2013. Ms. Zhou has been Vice Chairman of U-Home Group Holdings Limited. S ...


CEO Compensation Analysis

Wen Chuan's remuneration is lower than average for companies of similar size in Hong Kong.

Wen Chuan's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.2yrs

Average Tenure

53yo

Average Age

The tenure for the Meilleure Health International Industry Group management team is about average.


Board Age and Tenure

3.9yrs

Average Tenure

57yo

Average Age

The tenure for the Meilleure Health International Industry Group board of directors is about average.


Insider Trading

More shares have been bought than sold by Meilleure Health International Industry Group individual insiders in the past 3 months.


Recent Insider Transactions

BuyHK$4,260,53805 Sep 19
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares8,382,000
Max PriceHK$0.51
BuyHK$5,742,99514 Jun 19
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares8,772,000
Max PriceHK$0.65
BuyHK$792,00212 Jun 19
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares1,200,000
Max PriceHK$0.66
BuyHK$4,129,60904 Jun 19
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares6,600,000
Max PriceHK$0.63
BuyHK$3,312,43520 May 19
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares4,500,000
Max PriceHK$0.74
BuyHK$2,430,00317 May 19
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares3,000,000
Max PriceHK$0.81
BuyHK$13,649,99927 Apr 19
Wentao Zeng
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen & Executive Director
Shares15,000,000
Max PriceHK$0.91
BuyHK$39,131,81827 Apr 19
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares43,002,000
Max PriceHK$0.91
SellHK$3,276,41311 Apr 19
Eagle Best Limited
EntityCompany
Shares2,292,000
Max PriceHK$1.43
SellHK$13,565,27711 Apr 19
Eagle Best Limited
EntityCompany
Shares9,180,000
Max PriceHK$1.48
SellHK$5,096,53710 Apr 19
Eagle Best Limited
EntityCompany
Shares3,390,000
Max PriceHK$1.50
SellHK$144,00010 Apr 19
Chi Wai Chau
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares90,000
Max PriceHK$1.60
SellHK$1,463,90004 Apr 19
Eagle Best Limited
EntityCompany
Shares1,248,000
Max PriceHK$1.17
BuyHK$499,43819 Oct 18
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares1,200,000
Max PriceHK$0.42
BuyHK$526,01712 Oct 18
Wen Chuan Zhou
EntityIndividual
Role
Chief Executive Officer
Vice Chairman & CEO
Shares1,320,000
Max PriceHK$0.40
BuyHK$51,03012 Oct 18
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares126,000
Max PriceHK$0.41
BuyHK$479,99911 Oct 18
Wen Chuan Zhou
EntityIndividual
Role
Chief Executive Officer
Vice Chairman & CEO
Shares1,200,000
Max PriceHK$0.40
BuyHK$766,91326 Sep 18
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares1,848,000
Max PriceHK$0.41
BuyHK$875,99818 Sep 18
Xuzhou Zhou
EntityIndividual
Role
Co-Chairman of the Board
Co-Chairmen of the Board
Shares2,460,000
Max PriceHK$0.36

Ownership Breakdown


Management Team

  • Man Chun Chu (59yo)

    Human Resources Manager

    • Tenure: 0yrs
  • Chun Xia Liu (57yo)

    Quality Director of KJP and Director of Yunnan Jiwa Pharm-Tech Co Ltd

    • Tenure: 0yrs
  • Dong Mei Luo (50yo)

    Executive Assistant to Chairman and COO of Kunming Jida Pharmaceutical Company Ltd

    • Tenure: 0yrs
  • Chen Bang Hua (64yo)

    President of Jiwa Rintech Holdings Limited and Executive Director of Jiwa Rintech Holdings Limited

    • Tenure: 0yrs
  • Pu Chun Feng (47yo)

    Chief of R&D Dept - Kunming Jida Pharmaceutical Company Ltd and Director of R&D Dept - Kunming Jida

    • Tenure: 0yrs
  • Man Fai Shek (44yo)

    Financial Controller

    • Tenure: 0yrs
  • Xuzhou Zhou (63yo)

    Co-Chairmen of the Board

    • Tenure: 0.3yrs
    • Compensation: HK$500.00k
  • Wen Chuan Zhou (36yo)

    Vice Chairman & CEO

    • Tenure: 6yrs
    • Compensation: HK$540.00k
  • Shu Pai Li (43yo)

    CFO & Company Secretary

    • Tenure: 0.2yrs
  • Wentao Zeng (56yo)

    Co-Chairmen & Executive Director

    • Tenure: 0yrs
    • Compensation: HK$120.00k

Board Members

  • Wilton Chau (58yo)

    Independent Non-Executive Director

    • Tenure: 6.1yrs
    • Compensation: HK$120.00k
  • Chun Xia Liu (57yo)

    Quality Director of KJP and Director of Yunnan Jiwa Pharm-Tech Co Ltd

    • Tenure: 0yrs
  • Chen Bang Hua (64yo)

    President of Jiwa Rintech Holdings Limited and Executive Director of Jiwa Rintech Holdings Limited

    • Tenure: 0yrs
  • Zhenhua Mao (55yo)

    Non-Executive Director

    • Tenure: 3.9yrs
    • Compensation: HK$120.00k
  • Xuzhou Zhou (63yo)

    Co-Chairmen of the Board

    • Tenure: 0.3yrs
    • Compensation: HK$500.00k
  • Wen Chuan Zhou (36yo)

    Vice Chairman & CEO

    • Tenure: 6yrs
    • Compensation: HK$540.00k
  • Guanjiang Gao (66yo)

    Independent Non-Executive Director

    • Tenure: 6.1yrs
    • Compensation: HK$120.00k
  • Wentao Zeng (56yo)

    Co-Chairmen & Executive Director

    • Tenure: 0yrs
    • Compensation: HK$120.00k
  • Peng Wu (36yo)

    Independent Non-Executive Director

    • Tenure: 0.3yrs

Company Information

Meilleure Health International Industry Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Meilleure Health International Industry Group Limited
  • Ticker: 2327
  • Exchange: SEHK
  • Founded:
  • Industry: Trading Companies and Distributors
  • Sector: Capital Goods
  • Market Cap: HK$2.435b
  • Shares outstanding: 4.27b
  • Website: https://www.meilleure.com.cn

Number of Employees


Location

  • Meilleure Health International Industry Group Limited
  • Tower 1
  • Unit 2906
  • Admiralty
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2327SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDOct 2003

Biography

Meilleure Health International Industry Group Limited, an investment holding company, trades in health care products, and construction and chemical materials in Hong Kong and Mainland China. It operates th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 12:41
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.